CN111886248B - GM-CSF或GM-CSF受体的配体用于在已接受Allo-HCT的患者中治疗恶性血液病 - Google Patents

GM-CSF或GM-CSF受体的配体用于在已接受Allo-HCT的患者中治疗恶性血液病 Download PDF

Info

Publication number
CN111886248B
CN111886248B CN201980020251.7A CN201980020251A CN111886248B CN 111886248 B CN111886248 B CN 111886248B CN 201980020251 A CN201980020251 A CN 201980020251A CN 111886248 B CN111886248 B CN 111886248B
Authority
CN
China
Prior art keywords
cells
csf
leukemia
mice
hct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980020251.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN111886248A (zh
Inventor
S·图格斯
B·比彻
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universität
Original Assignee
Zurich Universität
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18194549.4A external-priority patent/EP3623382A1/en
Application filed by Zurich Universität filed Critical Zurich Universität
Publication of CN111886248A publication Critical patent/CN111886248A/zh
Application granted granted Critical
Publication of CN111886248B publication Critical patent/CN111886248B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980020251.7A 2018-02-22 2019-02-22 GM-CSF或GM-CSF受体的配体用于在已接受Allo-HCT的患者中治疗恶性血液病 Active CN111886248B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP18158169 2018-02-22
EP18158169.5 2018-02-22
EP18189562 2018-08-17
EP18189562.4 2018-08-17
EP18194549.4 2018-09-14
EP18194549.4A EP3623382A1 (en) 2018-09-14 2018-09-14 Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US16/269,572 US11655293B2 (en) 2018-02-22 2019-02-07 Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
US16/269,572 2019-02-07
PCT/EP2019/054493 WO2019162472A1 (en) 2018-02-22 2019-02-22 Ligands to gm-csf or gm-csf-receptor for use in treatment of a haematologic malignancy in a patient having undergone allo-hct

Publications (2)

Publication Number Publication Date
CN111886248A CN111886248A (zh) 2020-11-03
CN111886248B true CN111886248B (zh) 2025-03-04

Family

ID=67616687

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980020251.7A Active CN111886248B (zh) 2018-02-22 2019-02-22 GM-CSF或GM-CSF受体的配体用于在已接受Allo-HCT的患者中治疗恶性血液病

Country Status (11)

Country Link
US (3) US11655293B2 (cg-RX-API-DMAC7.html)
EP (1) EP3755715A1 (cg-RX-API-DMAC7.html)
JP (1) JP7278296B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200123434A (cg-RX-API-DMAC7.html)
CN (1) CN111886248B (cg-RX-API-DMAC7.html)
AU (1) AU2019224550A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020017253A2 (cg-RX-API-DMAC7.html)
CA (1) CA3091536A1 (cg-RX-API-DMAC7.html)
MA (1) MA51893A (cg-RX-API-DMAC7.html)
MX (2) MX2020008792A (cg-RX-API-DMAC7.html)
WO (1) WO2019162472A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
MX2022011111A (es) * 2020-03-08 2023-03-02 Humanigen Inc Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante.
TW202317637A (zh) * 2021-08-26 2023-05-01 日商協和麒麟股份有限公司 與cd116及cd131結合之雙特異性抗體

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101501070A (zh) * 2006-02-08 2009-08-05 诺福泰克公司 抗原性gm-csf肽和针对gm-csf的抗体
CN103827143A (zh) * 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0009772A (pt) 1999-04-14 2002-01-08 Us Health Composições contendo imunotoxinas e agentes que inibem a maturação de células dendrìticas para induzir tolerância imune a um enxerto
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
ES2918209T3 (es) 2005-05-18 2022-07-14 Morphosys Ag Anticuerpos anti-GM-CSF y usos a partir de los mismos
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分
KR101481844B1 (ko) 2006-03-27 2015-01-13 메디뮨 리미티드 Gm-csf 수용체에 대한 결합 성분
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US8679502B2 (en) 2007-11-13 2014-03-25 Evec Inc. Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
CA2717987C (en) 2008-04-29 2018-11-13 Micromet Ag Inhibitors of gm-csf and il-17 for therapy
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
EP3514169B1 (en) 2010-11-26 2024-03-06 Molecular Partners AG Designed repeat proteins binding to serum albumin
SG11201408196RA (en) 2012-06-28 2015-03-30 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
CN104995210A (zh) 2012-09-20 2015-10-21 莫弗系统股份公司 类风湿关节炎的治疗
US9658228B2 (en) * 2013-01-30 2017-05-23 The Board of Trustees of the Leland University Junior University Method to detect the onset and to monitor the recurrence of chronic graft versus host disease in transplantation patients
JP6490419B2 (ja) 2014-12-24 2019-03-27 学校法人関西医科大学 制御性t細胞分化誘導剤
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101501070A (zh) * 2006-02-08 2009-08-05 诺福泰克公司 抗原性gm-csf肽和针对gm-csf的抗体
CN103827143A (zh) * 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途

Also Published As

Publication number Publication date
US20190256587A1 (en) 2019-08-22
US20210070851A1 (en) 2021-03-11
AU2019224550A1 (en) 2020-09-17
MX2020008792A (es) 2020-10-14
US12384839B2 (en) 2025-08-12
RU2020129401A (ru) 2022-03-22
KR20200123434A (ko) 2020-10-29
EP3755715A1 (en) 2020-12-30
MA51893A (fr) 2020-12-30
US20230340100A1 (en) 2023-10-26
JP7278296B2 (ja) 2023-05-19
CN111886248A (zh) 2020-11-03
US11655293B2 (en) 2023-05-23
MX2023001357A (es) 2023-02-27
BR112020017253A2 (pt) 2020-12-22
JP2021514368A (ja) 2021-06-10
RU2020129401A3 (cg-RX-API-DMAC7.html) 2022-03-22
CA3091536A1 (en) 2019-08-29
WO2019162472A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
JP6808688B2 (ja) T制御性細胞の増殖または枯渇方法
Cravedi et al. Immune cell‐derived C3a and C5a costimulate human T cell alloimmunity
US12384839B2 (en) Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
JP5525689B2 (ja) 過剰増殖性障害を処置するための組成物および方法
US20100291677A1 (en) Reducer of immunosuppression by tumor cell and antitumor agent using the same
US20200095321A1 (en) Methods for in vivo expansion of cd8+ t cells and prevention or treatment of gvhd
US20220241333A1 (en) Modulation of t cell cytotoxicity and related therapy
ES2912173T3 (es) Terapia celular basada en NK mejorada
JP2021521121A (ja) 自己免疫疾患を処置するための方法
US20220411500A1 (en) Treatment of fibrosis with combined blockade of il-6 and immune checkpoint
EP4281469A1 (en) T cells for use in therapy
RU2772132C2 (ru) Лиганды гм-ксф или рецептора гм-ксф для применения при лечении гемобластоза у пациента, перенесшего алло-тгк
Li et al. Treatment of a MyD88 inhibitor alleviates rejection and inflammation in xenotransplantation by inhibiting dendritic cells activation and trained immunity in macrophages
JP2024536217A (ja) 操作されたnk細胞及びその使用
EP3623382A1 (en) Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
Dou et al. Reconstituted CD74+ NK cells trigger chronic graft versus host disease after allogeneic bone marrow transplantation
Choi et al. Context-dependent roles for autophagy in myeloid cells in tumor progression
WO2024014523A1 (en) Anti-aqp3 antibody cancer therapy
US20250213687A1 (en) Therapeutic t cell product
Simms Investigating the crosstalk between hepatic stellate cells and antigen presenting cells in pancreatic cancer liver metastases
WO2024064724A1 (en) Compositions and methods for treating cancer
AU2016204339A1 (en) Compositions and methods for the treatment of infections and tumors
Loo Activation of natural killer T cells and dendritic cells with Caulobacter crescentus: Implications for developing tumour immunity
Besin et al. Research Article IFN Regulatory Factors 4 and 8 Expression in the NOD Mouse
HK1138021B (en) Compositions and methods for the treatment of infections and tumors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20390610